nach oben

Supportive Care in Cancer

Erschienen in:

01.12.2007 | Original Article

Endocrine symptom assessment in women with breast cancer: what a simple “yes” means

verfasst von: K. Ribi, J. Bernhard, K. Rufibach, B. Thürlimann, R. von Moos, T. Ruhstaller, A. Glaus, C. Böhme

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

To investigate the self-reported symptoms related to endocrine therapy in women with early or advanced breast cancer and the impact of these symptoms on quality of life (QL) indicators.

Materials and methods

Symptom occurrence was assessed by the Checklist for Patients on Endocrine Therapy (C-PET) and symptom intensity was assessed by linear analogue self-assessment (LASA) indicators. Patients also responded to global LASA indicators for physical well-being, mood, coping effort and treatment burden. Associations between symptoms and these indicators were analysed by linear regression models.

Main results

Among 373 women, the distribution of symptom intensity showed considerable variation in patients reporting a symptom as present. Even though patients recorded a symptom as absent, some patients reported having experienced that symptom when responding to symptom intensity, as seen for decreased sex drive, tiredness and vaginal dryness. Six of 13 symptoms and lower age had a detrimental impact on the global indicators, particularly tiredness and irritability.

Conclusions

Patients’ experience of endocrine symptoms needs to be considered both in patient care and research, when interpreting the association between symptoms and QL.

Armstrong TS (2003) Symptoms experience: a concept analysis. Oncol Nurs Forum 30(4):601–606PubMedCrossRef

Arndt V, Merx H, Sturmer T et al (2004) Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer 40(5):673–680PubMedCrossRef

Avis NE, Crawford S, Manuel J (2005) Quality of life among younger women with breast cancer. J Clin Oncol 23(15):3322–3330PubMedCrossRef

Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131–2139PubMedCrossRef

Baum M, Priestman T, West RR et al (1980) A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur J Cancer (Suppl 1):223–226

Bernhard J, Castiglione Gertsch M, Schmitz SF et al (1999) Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 35(6):913–920PubMedCrossRef

Bernhard J, Hürny C, Coates AS et al (1997) Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol 8(9):825–835PubMedCrossRef

Bernhard J, Maibach R, Thurlimann B et al (2002) Patients’ estimation of overall treatment burden: why not ask the obvious? J Clin Oncol 20(1):65–72PubMedCrossRef

Bernhard J, Sullivan M, Huerny C et al (2001) Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84(9):1156–1165PubMedCrossRef

10.

Bernhard J, Thurlimann B, Schmitz SF et al (1999) Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol 17(6):1672–1679PubMed

11.

Bernhard J, Zahrieh D, Castiglione-Gertsch M et al (2007) Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. J Clin Oncol 25(3):263–270PubMedCrossRef

12.

Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18(22):3748–3757PubMed

13.

Carpenter JS, Andrykowski MA (1999) Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 26(8):1311–1317PubMed

14.

Coates A, Gebski V, Bishop JF et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490–1495PubMedCrossRef

15.

Coster S, Fallowfield LJ (2002) The impact of endocrine therapy on patients with breast cancer: a review of the literature. Breast 11(1):1–12PubMedCrossRef

16.

Couzi RJ, Helzlsouer KJ, Fetting JH (1995) Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13(11):2737–2744PubMed

17.

Day R, Ganz PA, Costantino JP et al (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17(9):2659–2669PubMed

18.

Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467

19.

Fallowfield L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22(21):4261–4271PubMedCrossRef

20.

Fallowfield L, Fleissig A, Edwards R et al (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19(7):1885–1892PubMed

21.

Fallowfield LJ, Bliss JM, Porter LS et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917PubMedCrossRef

22.

Ganz PA, Desmond KA, Leedham B et al (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94(1):39–49PubMed

23.

Ganz PA, Kwan L, Stanton AL et al (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96(5):376–387PubMedCrossRef

24.

Ganz PA, Rowland JH, Desmond K et al (1998) Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16(2):501–514PubMed

25.

Glaus A, Boehme C, Thurlimann B et al (2006) Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 17(5):801–806PubMedCrossRef

26.

Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802PubMedCrossRef

27.

Hopwood P (1998) Living with advanced breast cancer: development and application of a clinical checklist for patients on endocrine therapy. Breast 7:14–21CrossRef

28.

Hürny C, Bernhard J, Bacchi M et al (1993) The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1(4):200–208PubMedCrossRef

29.

Hurny C, Bernhard J, Coates A et al (1996) Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 34(3):234–248PubMedCrossRef

30.

Hurny C, Bernhard J, Coates AS et al (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347(9011):1279–1284PubMed

31.

King MT, Kenny P, Shiell A et al (2000) Quality of life three months and one year after first treatment for early stage breast cancer: influence of treatment and patient characteristics. Qual Life Res 9(7):789–800PubMedCrossRef

32.

Kohler U (1997) Tolerability of endocrine treatment for advanced breast cancer: results of an international survey. Oncology 54(Suppl 2):23–26PubMed

33.

Nystedt M, Berglund G, Bolund C et al (2003) Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 21(9):1836–1844PubMedCrossRef

34.

Priestman TJ, Baum M (1976) Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1(7965):899–900PubMedCrossRef

35.

Rutqvist LE (2004) Adjuvant endocrine therapy. Best Pract Res Clin Endocrinol Metab 18(1):81–95PubMedCrossRef

36.

Schou I, Ekeberg O, Sandvik L et al (2005) Multiple predictors of health-related quality of life in early stage breast cancer. Data from a year follow-up study compared with the general population. Qual Life Res 14(8):1813–1823PubMedCrossRef

37.

Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23(28):6931–6940PubMedCrossRef

Titel: Endocrine symptom assessment in women with breast cancer: what a simple “yes” means
verfasst von: K. Ribi
J. Bernhard
K. Rufibach
B. Thürlimann
R. von Moos
T. Ruhstaller
A. Glaus
C. Böhme
Publikationsdatum: 01.12.2007
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 12/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0258-3

Springer Medizin

Endocrine symptom assessment in women with breast cancer: what a simple “yes” means

Abstract

Goals of work

Materials and methods

Main results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Goals of work

Materials and methods

Main results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2007

An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy

Diagnosis and management of hyponatremia in cancer patients

Oxidative stress in lymphocytes, neutrophils, and serum of oral cavity cancer patients: modulatory array of l-glutamine

Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia

A population-based study on the specific locations of cancer deaths in Taiwan, 1997–2003

Symptom and medication profiles among cancer patients attending a palliative care clinic

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie